Association of pharmacological biomarkers with treatment response and long-term disability in patients with psoriatic arthritis: results from the Outcomes of Treatment in Psoriatic Arthritis Study Syndicate

Meghna Jani; Hector Chinoy; Anne Barton; OUTPASS collaborators

doi:10.3899/jrheum.190253

Association of pharmacological biomarkers with treatment response and long-term disability in patients with psoriatic arthritis: results from the Outcomes of Treatment in Psoriatic Arthritis Study Syndicate

Meghna Jani, Hector Chinoy, Anne Barton, OUTPASS collaborators

Division of Musculoskeletal & Dermatological Sciences (L5)

Research output: Contribution to journal › Article › peer-review

58 Downloads (Pure)

Abstract

Objectives: To identify (a)whether TNFi-drug levels/anti-drug antibodies (ADAbs) are associated with treatment response and disability in psoriatic arthritis (PsA) patients (b)factors associated with TNFi-drug levels.

Methods: Patients were recruited from a national multi-centre prospective cohort with longitudinal serum samples and disease-activity scores/Health assessment Questionnaire(HAQ) measurement over 12-months.

Results: Adalimumab-drug levels were significantly associated with ΔDAS28 [β=0.055 (95%CI: 0.011, 0.099) p=0.014] and inversely with HAQ over 12-months [β=-0.022 (95%CI: -0.043, -0.00063]. Factors significantly associated with adalimumab drug levels were ADAb levels and body mass index.

Conclusions: Drug-level testing in adalimumab-initiated PsA patients may be useful in determining treatment response/disability over 12-months.

Original language	English
Journal	Journal of Rheumatology
Early online date	1 Aug 2019
DOIs	https://doi.org/10.3899/jrheum.190253
Publication status	Published - 2019

Keywords

Immunogenicity
drug levels
tumour-necrosis factor-α inhibitors
anti-drug antibodies
treatment response

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.3899/jrheum.190253

OUTPASS_brief report_Journal of Rheum_R1_cleanAccepted author manuscript, 485 KB

Fingerprint

Dive into the research topics of 'Association of pharmacological biomarkers with treatment response and long-term disability in patients with psoriatic arthritis: results from the Outcomes of Treatment in Psoriatic Arthritis Study Syndicate'. Together they form a unique fingerprint.

Arthritis Research UK Centre of Excellence in the Genetics of Rheumatic Diseases.
Worthington, J. (PI), Barton, A. (CoI), Black, G. (CoI), Crow, Y. (CoI), Eyre, S. (CoI), Raychaudhuri, S. (CoI) & Thomson, W. (CoI)
1/08/13 → 31/07/18
Project: Research

Cite this

@article{4f909f4d66db4e3a962d7e37cf6a2b1c,

title = "Association of pharmacological biomarkers with treatment response and long-term disability in patients with psoriatic arthritis: results from the Outcomes of Treatment in Psoriatic Arthritis Study Syndicate",

abstract = "Objectives: To identify (a)whether TNFi-drug levels/anti-drug antibodies (ADAbs) are associated with treatment response and disability in psoriatic arthritis (PsA) patients (b)factors associated with TNFi-drug levels.Methods: Patients were recruited from a national multi-centre prospective cohort with longitudinal serum samples and disease-activity scores/Health assessment Questionnaire(HAQ) measurement over 12-months. Results: Adalimumab-drug levels were significantly associated with ΔDAS28 [β=0.055 (95%CI: 0.011, 0.099) p=0.014] and inversely with HAQ over 12-months [β=-0.022 (95%CI: -0.043, -0.00063]. Factors significantly associated with adalimumab drug levels were ADAb levels and body mass index.Conclusions: Drug-level testing in adalimumab-initiated PsA patients may be useful in determining treatment response/disability over 12-months. ",

keywords = "Immunogenicity, drug levels, tumour-necrosis factor-α inhibitors, anti-drug antibodies, treatment response",

author = "Meghna Jani and Hector Chinoy and Anne Barton and {OUTPASS collaborators}",

year = "2019",

doi = "10.3899/jrheum.190253",

language = "English",

journal = "Journal of Rheumatology",

issn = "0315-162X",

publisher = "Journal of Rheumatology Publishing Co. Ltd",

}

TY - JOUR

T1 - Association of pharmacological biomarkers with treatment response and long-term disability in patients with psoriatic arthritis: results from the Outcomes of Treatment in Psoriatic Arthritis Study Syndicate

AU - Jani, Meghna

AU - Chinoy, Hector

AU - Barton, Anne

AU - OUTPASS collaborators

PY - 2019

Y1 - 2019

N2 - Objectives: To identify (a)whether TNFi-drug levels/anti-drug antibodies (ADAbs) are associated with treatment response and disability in psoriatic arthritis (PsA) patients (b)factors associated with TNFi-drug levels.Methods: Patients were recruited from a national multi-centre prospective cohort with longitudinal serum samples and disease-activity scores/Health assessment Questionnaire(HAQ) measurement over 12-months. Results: Adalimumab-drug levels were significantly associated with ΔDAS28 [β=0.055 (95%CI: 0.011, 0.099) p=0.014] and inversely with HAQ over 12-months [β=-0.022 (95%CI: -0.043, -0.00063]. Factors significantly associated with adalimumab drug levels were ADAb levels and body mass index.Conclusions: Drug-level testing in adalimumab-initiated PsA patients may be useful in determining treatment response/disability over 12-months.

AB - Objectives: To identify (a)whether TNFi-drug levels/anti-drug antibodies (ADAbs) are associated with treatment response and disability in psoriatic arthritis (PsA) patients (b)factors associated with TNFi-drug levels.Methods: Patients were recruited from a national multi-centre prospective cohort with longitudinal serum samples and disease-activity scores/Health assessment Questionnaire(HAQ) measurement over 12-months. Results: Adalimumab-drug levels were significantly associated with ΔDAS28 [β=0.055 (95%CI: 0.011, 0.099) p=0.014] and inversely with HAQ over 12-months [β=-0.022 (95%CI: -0.043, -0.00063]. Factors significantly associated with adalimumab drug levels were ADAb levels and body mass index.Conclusions: Drug-level testing in adalimumab-initiated PsA patients may be useful in determining treatment response/disability over 12-months.

KW - Immunogenicity

KW - drug levels

KW - tumour-necrosis factor-α inhibitors

KW - anti-drug antibodies

KW - treatment response

U2 - 10.3899/jrheum.190253

DO - 10.3899/jrheum.190253

M3 - Article

SN - 0315-162X

JO - Journal of Rheumatology

JF - Journal of Rheumatology

ER -

Association of pharmacological biomarkers with treatment response and long-term disability in patients with psoriatic arthritis: results from the Outcomes of Treatment in Psoriatic Arthritis Study Syndicate

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Projects

Arthritis Research UK Centre of Excellence in the Genetics of Rheumatic Diseases.

Cite this